The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models
- PMID: 24418903
- DOI: 10.1097/01.MIB.0000440815.76627.64
The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models
Abstract
Background: The abundance of Faecalibacterium prausnitzii, an abundant and representative bacterium of Firmicutes phylum, has consistently been observed to be lower in patients with Crohn's disease than in healthy individuals. We have shown that both F. prausnitzii and its culture supernatant (SN) have anti-inflammatory and protective effects in a TNBS-induced acute colitis mouse model. Here, we tested the effects of both F. prausnitzii and its SN in moderate and severe DNBS-induced chronic colitis mouse models.
Methods: Colitis was induced by intrarectal administration of DNBS. After either 4 or 10 days of recovery (severe and moderate protocols, respectively), groups of mice were intragastrically administered either with F. prausnitzii A2-165 or with its culture SN for 7 or 10 days. Three days before being sacrificed, colitis was reactivated by administration of a lower dose of DNBS. The severity of colitis at the time of being sacrificed was assessed by weight loss and macroscopic and microscopic scores. Myeloperoxidase (MPO) activity, cytokine levels, lymphocyte populations, and changes in microbiota were studied.
Results: Intragastric administration of either F. prausnitzii or its SN led to a significant decrease in colitis severity in both severe and moderate chronic colitis models. The lower severity of colitis was associated with down-regulation of MPO, pro-inflammatory cytokines, and T-cell levels.
Conclusions: We show, for the first time, protective effects of both F. prausnitzii and its SN during both the period of recovery from chronic colitis and colitis reactivation. These results provide further evidence that F. prausnitzii is an anti-inflammatory bacterium with therapeutic potential for patients with inflammatory bowel disease.
Comment in
-
Dual role of MAPK pathway in the regulation of intestinal barrier function.Inflamm Bowel Dis. 2014 Jul;20(7):E16. doi: 10.1097/MIB.0000000000000064. Inflamm Bowel Dis. 2014. PMID: 24859299 No abstract available.
-
The dual role of MAPK pathway in the regulation of intestinal barrier: the role of the commensal bacterium Faecalibacterium prausnitzii on this regulation.Inflamm Bowel Dis. 2014 Jul;20(7):E17-8. doi: 10.1097/MIB.0000000000000070. Inflamm Bowel Dis. 2014. PMID: 24859300 No abstract available.
Similar articles
-
Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics.ISME J. 2017 Apr;11(4):841-852. doi: 10.1038/ismej.2016.176. Epub 2017 Jan 3. ISME J. 2017. PMID: 28045459 Free PMC article. Review.
-
Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease.Gut. 2016 Mar;65(3):415-425. doi: 10.1136/gutjnl-2014-307649. Epub 2015 Jun 4. Gut. 2016. PMID: 26045134 Free PMC article.
-
Faecalibacterium prausnitzii Strain HTF-F and Its Extracellular Polymeric Matrix Attenuate Clinical Parameters in DSS-Induced Colitis.PLoS One. 2015 Apr 24;10(4):e0123013. doi: 10.1371/journal.pone.0123013. eCollection 2015. PLoS One. 2015. PMID: 25910186 Free PMC article.
-
Faecalibacterium prausnitzii and human intestinal health.Curr Opin Microbiol. 2013 Jun;16(3):255-61. doi: 10.1016/j.mib.2013.06.003. Epub 2013 Jul 3. Curr Opin Microbiol. 2013. PMID: 23831042 Review.
-
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients.Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16731-6. doi: 10.1073/pnas.0804812105. Epub 2008 Oct 20. Proc Natl Acad Sci U S A. 2008. PMID: 18936492 Free PMC article. Clinical Trial.
Cited by
-
Uncovering specific taxonomic and functional alteration of gut microbiota in chronic kidney disease through 16S rRNA data.Front Cell Infect Microbiol. 2024 Apr 19;14:1363276. doi: 10.3389/fcimb.2024.1363276. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38707511 Free PMC article.
-
Cell-Free Supernatant of Lactobacillus rhamnosus and Bifidobacterium breve Ameliorates Ischemic Stroke-Generated Neurological Deficits in Rats.Probiotics Antimicrob Proteins. 2024 Apr 24. doi: 10.1007/s12602-024-10256-w. Online ahead of print. Probiotics Antimicrob Proteins. 2024. PMID: 38656733
-
Faecalibacterium duncaniae as a novel next generation probiotic against influenza.Front Immunol. 2024 Mar 12;15:1347676. doi: 10.3389/fimmu.2024.1347676. eCollection 2024. Front Immunol. 2024. PMID: 38590519 Free PMC article.
-
Strain-Specific Anti-Inflammatory Effects of Faecalibacterium prausnitzii Strain KBL1027 in Koreans.Probiotics Antimicrob Proteins. 2024 Feb 27. doi: 10.1007/s12602-024-10213-7. Online ahead of print. Probiotics Antimicrob Proteins. 2024. PMID: 38411865
-
Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial.Nat Commun. 2024 Feb 23;15(1):1633. doi: 10.1038/s41467-024-45357-1. Nat Commun. 2024. PMID: 38395948 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous